We found that pretreating AML cells with MG132 significantly reversed the ANXA1‐induced NICD degradation after 3 h of treatment in the control group, while MG132 minimally affected the expression level of NICD in the ANXA1 knockdown group (Figure3A,B). Here, ANXA1 is linked to acute myeloid leukemia.